This report was first published by Endpoints News. To see the original version, click here
Genentech will pick up an RNAi candidate from SanegeneBio, a China and US biotech fresh off a $110 million Series B.
The Roche unit will pay $200 million upfront for the global license to one of the biotech’s RNAi programs and eventually could fork over as much as $1.5 billion in biobucks, SanegeneBio said Monday morning. The name of the program was kept under wraps.
您已阅读24%（458字），剩余76%（1456字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。